Table 1.
Baseline demographics of warfarin-treated patients
| Demographic characteristics | All patients (n = 207) |
|---|---|
| Age (years) | 47.4 ± 14.7 |
| Sex | |
| Male | 93 (44.9%) |
| Female | 114 (55.1%) |
| Race | |
| Egyptian | 207 (100%) |
| Height (cm) | 166.7 ± 8 |
| Weight (kg) | 77.9 ± 15.7 |
| Indication for warfarina | |
| Atrial fibrillation | 2 (0.96%) |
| Mitral valve replacement | 107 (51.7%) |
| Deep vein thrombosis | 34 (16.4%) |
| Pulmonary embolism | 5 (2.4%) |
| Cerebrovascular accident | 22 (10.6%) |
| Aortic valve replacement | 26 (12.6%) |
| Cardiomyopathy | 5 (2.4%) |
| Others | 7 (3.36%) |
| Most common concomitant diseaseb | |
| Hypertension | 41 (19.8%) |
| Hyperlipidemia | 39 (18.8%) |
| Diabetes | 24 (11.6%) |
| Most concurrent interacting medicationsc | |
| Aspirin | 34 (16.4%) |
| Glimiperide | 9 (4.3%) |
| Goal INR range | |
| 1.5–2.0 | 9 (4.33%) |
| 2.0–3.0 | 197 (95.19%) |
| 2.5–3.5 | 1 (0.48%) |
INR, international normalized ratio.
Data are expressed as mean ± standard deviation or n (%).
a
Patients might have more than one indication for warfarin therapy.
b
Patients might have more than one concomitant disease.
c
Patients might have taken more than one concomitant interacting medication.